Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 501–600 of 702
Yu, H., Chang, J. K., Zhong, W., & Ye, P. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.341.13600 · Cited by 4
Clinical burden of autosomal dominant polycystic kidney disease
Hung, P., Lin, C., Hung, K., Muo, C., Chung, M., Chang, C.-H., & Chung, C. (2020) · Aging · doi:10.18632/aging.102858 · Cited by 4
Tanpure, S. D., Kardile, R. D., & Liu, R. (2023) · Organic Chemistry Frontiers · doi:10.1039/d3qo00134b · Cited by 4
Chiu, M. H., Miller, R. J. H., Barry, R., Li, B., Har, B., Wilton, S. B., Knudtson, M. L., Howlett, J. G., & James, M. T. (2018) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358118804838 · Cited by 4
“Furthermore, randomized controlled trials of ACE-I/ARB in patients with early stage and advanced proteinuric CKD have demonstrated that these agents can be used effectively and safety in most patients across the stages of CKD.(32,33) Strengths of our study include the detailed characterization of a large cohort of HF…”
InfluentialSlowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00049-4 · Cited by 6
Metal-π-allyl mediated asymmetric cycloaddition reactions
de la Cruz‐Sánchez, P., & Pàmies, Ò. (2021) · Advances in catalysis · doi:10.1016/bs.acat.2021.11.003 · Cited by 4
The management of end-stage heart failure and reducing the risk of cardiorenal syndrome
Scully, P. R., & Goldsmith, D. J. A. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-610 · Cited by 7
Use of renin angiotensin system inhibitors in patients with chronic kidney disease
Adam, W. R., & Wright, J. R. (2016) · Internal Medicine Journal · doi:10.1111/imj.13060 · Cited by 4
Pathophysiology and clinical management of hyperkalemia in chronic kidney disease
Palmer, B. F., & Clegg, D. J. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08465-3 · Cited by 3
Yin, Y.-M., Zhao, Q.-S., Ma, J., Chen, L., Zhou, M.-Y., & Yan, S. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01923 · Cited by 3
Irlik, K., Kwiendacz, H., Ignacy, W., Grabska, A., Gumprecht, J., Lip, G. Y. H., & Nabrdalik, K. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2574492 · Cited by 3
“Over-activation of the renin – angiotensin – aldosterone system promotes glomerulosclerosis in the kidney and fibrosis in the atrium, while pharmacological blockade of this pathway can slow CKD progression and lower incident AF [15–18].”
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
Weir, M. R. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151688 · Cited by 4
Anand, S., Thomas, B., Remuzzi, G., RIELLA, M. C., Nahas, M. E., Naicker, S., & Dirks, J. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0518-9_ch13 · Cited by 4
Tran, P., Long, T., Smith, J., Kuehl, M. W., Mahdy, T., & Banerjee, P. (2022) · Open Heart · doi:10.1136/openhrt-2022-002101 · Cited by 3
Wang, J., Li, X., Zhang, Y., & Zhou, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1438695 · Cited by 4
Takeuchi, N., Takenoshita, E., Kato, F., Terajima, T., Ogawa, M., Suzuki, S., Fujii, T., Kobayashi, E., Sakurada, T., Satoh, N., et al. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0365-1 · Cited by 3
Benavente, D., Mrcp, C. D. C., & Ferro, C. J. (2010) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(10)70567-8 · Cited by 3
Gao, L., Wang, Z., Feng, S., Jiang, S., Ouyang, H., Shi, Y., & Shen, H. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314548868 · Cited by 3
“1262 Journal of the Renin-Angiotensin-Aldosterone System 16(4)”
InfluentialTsuchimoto, A., Masutani, K., Ueki, K., Nakagawa, K., Matsukuma, Y., Tanaka, S., Unagami, K., Kakuta, Y., Okumi, M., Noguchi, H., et al. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01827-1 · Cited by 3
García‐Prieto, A., Verdalles, Ú., & Goicoechea, M. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2020.12.025 · Cited by 4
Lin, S., Chang, S., Lin, C., Lin, C., Hsu, W., Chou, C.-H., Chi, C., Lin, C., Tu, C., Hsu, C. Y., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14476 · Cited by 3
Niu, P., Ren, X., Wu, M., Wan, S., Zheng, Y., Jiao, X., Yan, L., Cao, H., Yang, L., & Shao, F. (2022) · Medicine · doi:10.1097/md.0000000000028854 · Cited by 3
“Extensive experimental and clinical studies have implicated the RAS in the progression of renal injury.([16]) Our results indicated that the activation of intrarenal RAS was much higher in patients clinically diagnosed with AKI after cardiac surgery than that in the non-AKI group, which means that the activation of in…”
BackgroundCorreia, J. T. M., Paixão, M. W., de Souza, W. C., Lima, R. N., & de Jesus, I. S. (2022) · Synthesis · doi:10.1055/a-1953-1849 · Cited by 3
IRIS-Stage 4 CKD in a Dog: Diagnostic Approaches and Staging of Chronic Kidney Disease: A Case Study
Gunawan, M., Amelia, F., Resyana, N. N. Y., ZulfaIchsanniyati, R. C. F., Zaenab, S., & Widyaputri, T. (2023) · Journal of Experimental Biology and Agricultural Sciences · doi:10.18006/2023.11(1).216.225 · Cited by 3
Morris, S., & Manickavasagam, V. (2023) · Australian Journal of General Practice · doi:10.31128/ajgp-04-22-6386 · Cited by 3
Les promesses de la néphroprotection à l’épreuve des faits
Krummel, T., Faller, A.-L., Bazin, D., & Hannedouche, T. P. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.04.021 · Cited by 3
“tome 40 > n811 > novembre 2011 des IEC a été étendu aux patients à un stade avancé de l’IRC (< 30 mL/min/1,73 m(2)) [27].”
Stratégies pour ralentir la progression des maladies rénales chroniques
Combe, C., Rigothier, C., Vendrely, B., Chauveau, P., Rigalleau, V., & Lasseur, C. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.04.034 · Cited by 3
The Role of Systemic Blood Pressure in the Progression of Chronic Kidney Disease
Griffin, K. A., Pothugunta, K. S., Polichnowski, A. J., & BIDANI, A. K. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0450-9 · Cited by 3
Epstein, M., & Pitt, B. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw222 · Cited by 3
“Marked underrepresentation of patients with chronic kidney disease in randomized clinical trials of cardiovascular interventions Despite the increased CVD mortality, there has been a dearth of interventional cardiovascular RCTs in the CKD population, especially those with Stages 4–5 CKD.11–13 Furthermore, many patient…”
ResultInfluentialThuraisingham, R. C., & Adu, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-5101-2.00067-4 · Cited by 4
Wang, H., Zhang, C., Xiao, Q., Dou, H., Chen, Y., Gu, C., & Cui, M.-J. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6301 · Cited by 3
Mitch, W. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00132-9 · Cited by 7
Geriatric Pharmacotherapy Updates
Guay, D. R. P. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/s1543-5946(10)80009-1 · Cited by 3
OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Zachariah, D., Kalra, P. A., & Kalra, P. R. (2009) · Journal of Renal Care · doi:10.1111/j.1755-6686.2009.00069.x · Cited by 3
“There was also a 52% reduction in the level of proteinuria, and a reduction of 23% in the rate of decline in renal function (Hou et al. 2006).”
BackgroundInfluentialPrevention of Progressive Renal Failure
Taal, M. W. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50064-2 · Cited by 3
Should Renin-Angiotensin System Blockade Be Avoided in Patients With Declining Kidney Function?
Weir, M. R., Chen, D. C., & Ku, E. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.003 · Cited by 3
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.62 · Cited by 3
Shulman, R., Yang, W. P., Cohen, D. L., Reese, P. P., Cohen, J. B., Appel, L. J., Chen, J., Cohen, D. L., Feldman, H. I., Go, A. S., et al. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101159 · Cited by 2
Patel, S. S., Heidenreich, P. A., Morgan, C. J., Faselis, C. J., Zhang, S., Wu, W.-C., Lam, P. H., Palant, C. E., Zeng‐Treitler, Q., Fonarow, G. C., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.10.002 · Cited by 2
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis
Wu, Z., He, Y., Deng, H., Tan, Y., Gao, W., Yin, J., Zeng, Z., Sun, J., Zhang, L., Li, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1773015 · Cited by 2
“This leads to glucose-dependent insulin secretion, reduced circulating glucagon, and consequent blood glucose reduction (Hou et al., 2006).”
Chen, L., Shi, W.-D., Liu, S.-S., & Deng, J. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c02200 · Cited by 2
Hypertension artérielle et insuffisance rénale
Pruijm, M., Battegay, E., & Burnier, M. (2009) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2009.06872 · Cited by 2
Mangat, S., & Atlas, S. A. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0020-0 · Cited by 2
Yang, X., Ma, F., Bai, M., Wang, Y., Jia, Q., Dong, R., Liu, C., & Sun, S. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1956536 · Cited by 2
“When the serum creatinine exceeds 3mg/dL, 80% of patients do not receive RASi agents because of the associated adverse events [6].”
BackgroundChlorthalidone and Advanced Chronic Kidney Disease
Furgeson, S. B., & Linas, S. L. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01380222 · Cited by 2
“To date, there are high-quality data that reninangiotensin system (RAS) antagonists slow CKD progression in patients with stage 4 CKD (3).”
BackgroundMethodSynthesis of Trifluoroacetamidoketones by Acylation of Ferrocene with In Situ Protected Amino Acids
Piotrowicz, M., Masłowska, N., Dziewiątkowska, R., Makal, A., & Rudolf, B. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02717 · Cited by 3
Cardiorenal versus Renocardiac Syndrome
Sarraf, M., Masoumi, A., & Schrier, R. W. (2010) · Springer eBooks · doi:10.1007/978-88-470-1463-3_2 · Cited by 2
“This beneficial effect of ACE inhibitors is proven in a prospective study in nondiabetic patients with HF who had a serum creatinine as high as 5 mg/dl [26].”
BackgroundZhang, X., & Hou, F. F. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200702010-00014 · Cited by 2
“6%) was much lower among patients with basal serum creatinine of 133-265 μmol/L, even though these patients receive the same dose of benazepril.(3) Likewise, in a post hoc analysis of REIN study, the incidence of ESRD was higher among patients with worse baseline glomerular filtration rate (GFR) than among those with…”
BackgroundResultSelf-citationPöschel, K. A., & Wolf, G. (2006) · Der Nephrologe · doi:10.1007/s11560-006-0041-3 · Cited by 2
“Auch bei schwerer Nierenfunktionseinschränkung ist die Therapie mit einem ACE-Hemmer progressionshemmend [13].”
BackgroundThe Interdisciplinary Clinic for Chronic Kidney Disease
Pisoni, R., Bauer, C. A., Yee, J., & Campbell, R. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00056-5 · Cited by 3
Benazepril: Nephropathy (Non-diabetic)
Generali, J. A., & Cada, D. J. (2016) · Hospital Pharmacy · doi:10.1310/hpj5104-293 · Cited by 2
BETA-BLOCKERS AND RENOPROTECTION: THE POTENTIAL OF CARVEDILOL
Murkamilov, I. T., Sabirov, I. S., Fomin, V. V., & Yusupov, F. A. (2017) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2017-13-3-422-426 · Cited by 3
Oh, H. J., Kim, C. T., & Ryu, D. (2019) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2019.17.2.25 · Cited by 2
Capuano, I., Buonanno, P., Riccio, E., Bianco, A., & Pisani, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206184 · Cited by 3
Pharmacological intervention of hypertension in proteinuric chronic kidney disease: how and what?
Hou, F. F. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200805010-00016 · Cited by 2
Self-citationProdrug Strategies to Enhance Oral Drug Absorption
Boddu, S. H. S., Kwatra, D., & Mitra, A. K. (2011) · Wiley eBooks · doi:10.1002/9781118067598.ch22 · Cited by 2
The Evolving Chinese Health Care System
Mahmoudi, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmc052753 · Cited by 2
Bangalore, S., Fakheri, R. J., Toklu, B., & Messerli, F. H. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.020 · Cited by 2
Zeitler, E. M., & Mottl, A. K. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12401022 · Cited by 2
Chronic Kidney Disease in the Elderly
Weiss, J. W., & Woodell, T. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00005-7 · Cited by 2
Potassium Metabolism in Chronic Kidney Disease
Palmer, B. F., & Clegg, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00040-1 · Cited by 1
Jeon, J., Shin, D. W., Park, S. H., Jung, J.-H., Lee, K., Lee, J. E., Huh, W., Han, K., & Jang, H. R. (2024) · American Journal of Nephrology · doi:10.1159/000541832 · Cited by 3
Spencer, S., & Bhandari, S. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001076 · Cited by 1
Sigmund, L. M., Seifert, T., Halder, R., Bergonzini, G., Johansson, M. J., Norrby, P., Jorner, K., & Kabeshov, M. (2025) · Angewandte Chemie · doi:10.1002/ange.202510533 · Cited by 1
Zhang, Q., Fang, B., Wei, G., Li, C., Zhang, F., & Shen, Z. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c02833 · Cited by 1
Hutton, B., Yazdi, F., Hersi, M., Catalá-López, F., Tetzlaff, J., Kanji, S., Fergusson, D. A., Bjerre, L. M., Coyle, D., Coyle, C., et al. (2014) · uO Research (University of Ottawa) · Cited by 3
Swift, P. A., & Andrews, P. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02472.x · Cited by 1
An ACE in the Hole for Patients With Advanced Chronic Kidney Disease?
Park, M., & Hsu, C. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12176 · Cited by 2
Magalhães, P. P., de Oliveira, R. C., Ponce, D., & Zuliani, S. R. Q. A. (2019) · Revista Brasileira de Educação Médica · doi:10.1590/1981-5271v43suplemento1-20190117 · Cited by 1
Schmitt, R. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00525-y · Cited by 1
Goldman, J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_7 · Cited by 1
Porter, G. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-84843-3_1 · Cited by 1
Tomaru, R. (2022) · Cureus · doi:10.7759/cureus.25087 · Cited by 1
“The antihypertensive and improvement-of-prognosis effects of these RASi are controversial in the patient population [8-11], especially in elderly patients undergoing hemodialysis (HD).”
BackgroundClase, C. M., & Smyth, A. (2015) · Europe PMC (PubMed Central) · Cited by 1
Base-Promoted Ring Expansion Reaction of 4-Quinolones To Access Benzazepinones
Jiang, F., Fan, R., Chen, B., Mu, T., Liu, X., Xu, J., Tan, X., & Wu, J. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c03016 · Cited by 1
Role of ACE Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7380-0_6 · Cited by 1
Hohenstein, K., & Watschinger, B. (2008) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0558-3 · Cited by 3
“[47] Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, LiangM,WangGB, Liu ZR, GengRW.”
BackgroundLa, Z., Fu, H., Bai, L., Liu, X., Zeng, Y., & Wu, Y. (2014) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2014.6999361 · Cited by 1
“For example, angiotensin-converting enzyme inhibitors (ACEIs) or Angiotensin II receptor antagonists (ARBs) were proved to be able to reduce excretion of urinary protein and slow down progression of CKD [6, 7].”
BackgroundAngiotensin-converting enzyme inhibitor-induced angioedema may not be a class-related event
Farhat, H. A. (2013) · Journal of emergency medicine, trauma & acute care · doi:10.5339/jemtac.2012.14 · Cited by 1
Maqsood, K., Siddiqui, A. M., & Teehan, G. S. (2013) · Open Journal of Nephrology · doi:10.4236/ojneph.2013.33024 · Cited by 1
“enrolled 422 patients with non-diabetic CKD and randomly assigned them to benazepril or placebo plus other antihypertensive therapy to attain a systolic and diastolic pressure below 130 and 80 mmHg, respectively [16].”
BackgroundEtiology, Diagnosis, and Management of Chronic Renal Insufficiency in the Aged
Rosenstock, J. L., & Michelis, M. F. (2007) · Springer eBooks · doi:10.1007/978-0-387-72659-5_23 · Cited by 1
“Indeed, a recent study in the New England Journal of Medicine [ 42 ] found that patients with advanced CRI (serum creatinine 436 Jordan L. Rosenstock and Michael F. Michelis”
BackgroundEthnicity and Chronic Kidney Disease in China
Gao, B., Wang, J., Zhang, L., & Zhuang, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00012-7 · Cited by 1
Ueda, Y., Ookawara, S., Miyazawa, H., Ito, K., Hirai, K., Hoshino, T., & Morishita, Y. (2019) · Cureus · doi:10.7759/cureus.5561 · Cited by 1
“In the treatment strategy of CKD patients, renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are usually administered to improve arterial hypertension and intraglomerular hypertension, which preserves or improves renal function…”
BackgroundShen, Y., Wang, J., Chen, H., Li, M., & Chen, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1739914 · Cited by 1
Yuan, S., Liu, Y., He, W., Jin, J., Liu, L., & He, Q. (2021) · Nephrology · doi:10.1111/nep.13915 · Cited by 1
“Furthermore, RASi can slow the progression of chronic kidney damage by suppressing proteinuria.(23,24) Initial treatment with RASi being commonly associated with EWKF gained our attention, and has been ascribed to hemodynamic changes and thought to be an indicator of better prognosis in the past,(2,6) but found to be…”
ResultZusammenhang zwischen kardiovaskulären Erkrankungen und Progression von Nierenerkrankungen
Ivens, K., & Grabensee, B. (2006) · Der Nephrologe · doi:10.1007/s11560-006-0044-0 · Cited by 1
Danyliuk, I. Y., Tolmachova, V. S., Rusanov, E. B., & Вовк, М. В. (2021) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-021-03042-x · Cited by 1
(2006) · Kidney International · doi:10.1038/sj.ki.5000288 · Cited by 1
Dupud, R., Thushara, R., Merugu, K. K., Suresh, C. H., & Ramesh, R. (2024) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202400450 · Cited by 1
Prise en charge de l’hypertension artérielle d’origine rénale
Fesler, P., & Ribstein, J. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74748-0 · Cited by 1
Divergences in antihypertensive therapy in special situations in nephrology
Lemos, M. M., Pedrosa, A. C., Tavares, A. P. D. S., Góes, M. Â., Draibe, S. A., & Sesso, R. (2008) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802008000100007 · Cited by 1
Ralentissement de la progression de la maladie rénale chronique : actualités
Esnault, V. L. M. (2007) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(07)78748-5 · Cited by 1
Renin–angiotensin inhibitors in stage 4 chronic kidney disease
Hirsch, S. (2006) · Kidney International · doi:10.1038/sj.ki.5001837 · Cited by 1
Wesley, D. J., Ortíz, E., Reisin, E., Rich, M. W., Schocken, D. D., Frishman, M. A., Jaigobin, C. S., Kostis, J. B., Mancia, G., Oparil, S., et al. (2011) · Cited by 2
Thrombotic Risk Assessment in End Stage Renal Disease Patients on Renal Replacement Therapy
Sharma, S. (2016) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.17114 · Cited by 1
Kang, Y.-X., Lin, X., Ding, Y., Pan, X., He, S.-X., & Shan, P. (2019) · Diabetes Care · doi:10.2337/dc18-2288 · Cited by 1
“However, the studies mentioned above either have a shorter follow-up duration (2) or lack data specific to diabetes (3,4).”
BackgroundAdarkwah, C. C. (2015) · Research Publications (Maastricht University) · doi:10.26481/dis.20150910ca · Cited by 1
Predictors of renal and patient outcomes in chronic kidney disease
Methven, S. (2012) · Enlighten: Theses (The University of Glasgow) · Cited by 2
Weir, M. R., & Portocarrero, M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-963-5_8
“A recent paper by Hou et al. demonstrated that even patients with nondiabetic kidney disease with a creatinine as high as 5.0 mg/dL can be safely and effectively treated with renin–angiotensin system blockade ( 49 ).”
BackgroundInfluential
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.